Ozempic & GLP-1 Arbitration Leads
Most Ozempic and GLP-1 lead lists are contact information with a drug name attached — no confirmed prescription, no medical record, no confirmed arbitration agreement. Our Ozempic arbitration leads are screened claimants: a documented injury, a subscription or telehealth provider whose terms route disputes to arbitration, and a case file ready for your intake team to review.
I. The Problem
Ozempic and GLP-1 litigation is now one of the most heavily marketed mass-tort categories in the country, which means the lead market around it is flooded with recycled contact lists — people who searched the drug's name once, with no confirmed prescription history, no documented injury, and no idea their subscription-pharmacy or telehealth provider's terms of service quietly route any dispute into arbitration rather than the federal MDL. Firms buying those lists pay for volume and inherit the screening work themselves.
II. The Marketplace Model
ArbitrationIntel is a three-side marketplace, not a lead broker. Accredited capital funds campaigns aimed at patients who used semaglutide or tirzepatide through telehealth weight-loss platforms and compounding-pharmacy subscriptions — the channel where arbitration clauses, not court filings, typically govern the dispute. Every response is checked against a documented injury and the underlying provider agreement before your firm ever sees a name.
Your firm reviews a case file, not a spreadsheet of unverified contacts.
III. Claim Profile & Screening Criteria
Confirmed use
A documented semaglutide or tirzepatide prescription of sufficient duration, sourced from pharmacy or telehealth-provider records — not a self-report.
Documented injury
Medical records tying gastroparesis, bowel obstruction, NAION, gallbladder disease, or a clotting event to the treatment period, including any ER visit, hospitalization, or surgery.
Confirmed arbitration path
The telehealth platform or pharmacy's terms of service are checked to confirm a dispute would actually be routed to arbitration, not left ambiguous.
No disqualifying confound
Pre-existing conditions that would fully explain the injury independent of GLP-1 use are flagged and screened out before delivery.
Capacity fit
Claimants are matched to firms with open Ozempic and GLP-1 intake capacity — never distributed to more firms than the volume supports.
IV. How A Claimant Reaches Your Firm
Funded Outreach
Campaigns reach patients who used GLP-1 medications through telehealth and subscription-pharmacy channels — the population most likely to hold an arbitration agreement rather than a court claim.
Medical-Record Verification
Prescription history and injury documentation are collected and checked against the claim profile before the file moves forward.
Arbitration-Agreement Confirmation
The provider's terms of service are reviewed to confirm arbitration governs the dispute, and on what terms.
Capacity Match
Qualified claimants are matched to a firm on the panel with open Ozempic intake capacity in the relevant jurisdiction.
Warm Handoff
Your intake team receives a screened case file, not a cold contact — ready for the retainer conversation.
V. The Flywheel — Proof, Not A Promise
Capital
Accredited funders back Ozempic outreach, targeting a measured-risk return.
Deployment is per-vertical, not pooled-blind. Returns are targeted, not guaranteed, and available to accredited investors only.
Your Firm
Screened Ozempic claimant flow, without an ad-spend line item.
Medical-record verification and arbitration-agreement confirmation happen upstream. You review the case, not the campaign.
Claimants
Patients injured by GLP-1 treatment are matched to counsel who takes the case.
Every file is screened for injury and agreement before a firm ever sees it.
This is the same engine behind the case results in the Bennett Legal case study — the better a campaign performs for one vertical, the better it performs across the panel.
VI. Questions Firms Ask
What is an Ozempic arbitration lead?
A claimant who used semaglutide or tirzepatide through a telehealth or subscription-pharmacy provider whose terms of service route disputes to arbitration, with a documented injury and prescription history verified before your firm sees the file.
How are Ozempic claimants screened before they reach my firm?
Each file is checked for confirmed prescription duration, injury documentation from medical records, and a confirmed arbitration clause in the underlying provider agreement — claimants who don't clear all three are never delivered.
Why are some GLP-1 injury claims arbitrated instead of joining the federal MDL?
The federal MDL (In re: GLP-1 Receptor Agonists Litigation) generally addresses manufacturer claims. Patients who obtained their prescription through a telehealth platform or subscription pharmacy are often bound by that provider's separate arbitration agreement, which is a distinct claimant pool this panel focuses on.
What does it cost my firm to add Ozempic capacity?
Panel terms are set case type by case type and confirmed before you sign on. There is no ad-spend line item — your firm pays only for claimants who've already cleared screening.
How fast can my firm start receiving Ozempic claimant flow?
Once your practice areas, jurisdictions, and intake capacity are confirmed on a call, matching against the current screened pipeline typically begins within days, not weeks.
Elsewhere On The Panel
VII. Join The Panel
Book a 15-minute call to review current Ozempic and GLP-1 claimant coverage in your practice areas, or apply to join the panel by email.
Not ready to talk? Request the Mass Arbitration Lead Economics report — the data behind claimant-flow ROI, before you get on a call.